Teratogenic risk of antiepileptic drugs assessed

Key Point

A prospective analysis of data from a European pregnancy registry of antiepileptic drugs published in Lancet Neurology showed that use of valproate had the highest prevalence of major congenital abnormalities (10.3%), whereas agents such as oxcarbazepine (3.0%), lamotrigine (2.9%), and levetiracetam (2.8%) had the lowest prevalence. Also, dose dependency in prevalence was noted for select agents, with higher dosages having greater teratogenic risks than lower dosages.

Source URL:

http://www.aphadruginfoline.com/neurology/teratogenic-risk-antiepileptic-drugs-assessed
Misinformation and barriers to emergency contraception persist

Key Point

Adolescent females inquiring about OTC emergency contraception (EC) were less likely to receive accurate information from pharmacy staff compared with adolescent males and physicians, and about 10% of adolescent patients regardless of gender were denied access to EC on the basis of their age, indicating that misinformation and access barriers to EC continue to exist, according to a report published in the Journal of Adolescent Health.

Source URL:

Can use of menthol-containing cough drops worsen a cough?

Key Point

Results of an observational study published in the Journal of the American Board of Family Medicine showed that use of cough drops was associated with a longer duration of cough compared with nonuse. A significant association was seen between cough severity and the average menthol dose per cough drop, the number of cough drops consumed per day, and the total amount of menthol consumed per day.

Source URL:

Costs of anticancer drugs have risen substantially, while clinical benefits remain similar

Key Point

An observational analysis assessing trends in costs of anticancer drugs over a 10-year period compared with clinical benefits in the Journal of Oncology Practice found that monthly prices of these medications increased by a mean of 9% annually, and incremental drug costs increased by 21% annually. The magnitude of clinical benefits of these agents did not experience a similar proportional positive change.

Source URL:

http://www.aphadruginfoline.com/oncology/costs-anticancer-drugs-have-risen-substantially-while-clinical-benefits-remain-similar
Updated guideline released on use of disease-modifying therapies for patients with MS

Key Point

In April 2018, the American Academy of Neurology (AAN) published an updated guideline in Neurology on the use of disease-modifying agents for patients with multiple sclerosis (MS). The guideline focuses on who should start these therapies, which agents to initiate, switching between medications, and when to stop treatment.

Source URL:
Select antidiabetic medications associated with better mortality outcomes in patients with type 2 diabetes

Key Point

Use of sodium–glucose cotransporter 2 (SGLT-2) inhibitors and glucagon-like peptide 1 (GLP-1) agonists were both associated with significantly lower all-cause mortality and cardiovascular (CV) mortality compared with dipeptidyl peptidase 4 (DPP-4) inhibitors and placebo/no treatment in patients with type 2 diabetes, according to results of a systematic review and network meta-analysis published in JAMA.

Source URL:
Alerts and Recalls

Generic Name (Trade Name—Company)       Uses/Notes

June 1, 2018

**Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules**

*(Taytulla Softgel Capsules—Allergen)*

**Discovery of out-of-sequence capsules prompts recall of oral contraceptive**

*Allergan issued* a voluntary recall of one lot (#5620706, Expiry May-2019) of norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules 1 mg/20 mcg, 6 x 28 physicians sample pack, indicated for use by women to prevent pregnancy. Allergan recently identified, through a physician report, that four placebo capsules were placed out of order in a sample pack. Specifically, the first four days of therapy had four nonhormonal placebo capsules instead of active capsules.

Oral contraceptive capsules that are taken out of sequence may place the user at risk for contraceptive failure and unintended pregnancy. The reversed order may not be apparent to either new users or previous users of the product, increasing the likelihood of taking the capsules out of order.

The product was distributed Nationwide to healthcare providers.

Please refer [here](http://www.aphadruginfoline.com/alerts-and-recalls/discovery-out-sequence-capsules-prompts-recall-oral-contraceptive) to the affected lot number as well as photographs of the affected product.

Source URL:

Supplemental Approvals

Generic Name (Trade Name—Company) | Uses/Notes
--- | ---
June 2, 2018 | Estradiol vaginal inserts (Imvexxy—TherapeuticsMD) FDA approved estradiol vaginal inserts for treatment of moderate to severe vaginal pain associated with sexual activity, a symptom of vulvar and vaginal atrophy (VVA) due to menopause. It is the only product in its therapeutic class to offer a 4-mcg and 10-mcg dose, the 4 mcg representing the lowest approved dose of vaginal estradiol available.

VVA is a component of genitourinary syndrome of menopause, which may include but is not limited to genital symptoms of dryness, burning, and irritation; sexual symptoms such as decreased lubrication, discomfort, and pain; and urinary symptoms such as urgency, dysuria, and recurrent urinary tract infections. VVA is a chronic, progressive condition that leads to distressing symptoms and can worsen if not treated.

The product’s mechanism of action is re-estrogenization of the tissue in and around the vagina. The formulation ensures that it dissolves completely without mess, so patients can use it any time of day by placing the softgel capsule in the lower part of the vagina to treat the vulva and vagina.

The inserts are administered daily for 2 weeks, followed by only twice-a-week dosing.

The most common adverse reaction (incidence >3%) and greater than placebo was headache. No clinically significant differences in adverse events were observed between treatment and placebo groups.

Source URL:
Alerts and Recalls

Generic Name (Trade Name—Company)  Uses/Notes

June 2, 2018  

Fluticasone propionate nasal spray  
(No trade names—Apotex Corp.)  
Nasal spray may contain small glass particles  

FDA announced a recall of one lot of fluticasone propionate nasal spray 50 mcg per spray, 120 metered sprays (lot# NJ4501, expiration date July 2020). The product may contain small glass particles that could block the actuator, impact the functionality of the pump, and cause local trauma to the nasal mucosa in individuals who use it.

The issue was discovered through a customer complaint.

The spray is indicated for treatment of seasonal and perennial allergic rhinitis and management of sinus pain and pressure associated with allergic rhinitis in patients 4 to 17 years of age.

Patients, wholesalers, retailers, hospitals, or institutions should stop use and distribution of the remaining units and quarantine immediately.

Source URL:  
FDA warns of stolen fertility drugs

June 2, 2018

**Follitropin alfa injection**

*(Gonal-f RFF Redi-ject, Gonal-f Multi-Dose—EMD Serono)*

FDA warns of stolen fertility drugs

FDA is alerting health professionals, patients, and the drug supply chain of stolen injectable fertility medications. Gonal-f RFF Redi-ject, Gonal-f Multi-Dose (follitropin alfa injection). Patients who have product with these lot numbers should not use them.

All product with these lot numbers were in this stolen shipment. The lot numbers are located on the flap of each box, below the tamper-proof seal and next to the 2D barcode.

The products were stolen in Italy on May 17, 2018, and were intended to be shipped to the United States. EMD Serono of Rockland, MA, reported the theft of more than 16,000 packages of follitropin alfa injection to FDA on May 18, 2018.

Drug supply chain stakeholders that receive or possess these lot numbers must notify FDA via Form FDA 3911. Anyone who has received suspicious or unsolicited offers to purchase follitropin alfa injection products since May 17, 2018, should contact FDA Office of Criminal Investigations at 800-551-3989.

Drug supply chain stakeholders should continue to remain vigilant when buying or selling these products and check the lot number to prevent stolen product from entering the drug supply chain.

Patients, health professionals, and drug supply chain stakeholders should check the product and label for signs of tampering before using.

FDA also reminds health professionals, patients, and drug supply chain stakeholders to purchase products only from licensed wholesale distributors and pharmacies. See FDA's Know Your Source and BeSafeRx programs for more information.

**Source URL:**

Baricitinib

**Eli Lilly and Incyte announced** FDA approval of a 2-mg dose of baricitinib, a once-daily oral medication to treat moderately to severely active rheumatoid arthritis (RA) in adults who have had an inadequate response to one or more tumor necrosis factor (TNF)–inhibitor therapies.

Use of baricitinib in combination with other Janus kinase inhibitors or biologic disease–modifying antirheumatic drugs (bDMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine, is not recommended. Baricitinib may be used as monotherapy or in combination with methotrexate or other nonbiologic DMARDs.

Approval was based on a clinical trial program that included the RA-BEACON study, a randomized, double-blind, placebo-controlled study in which patients were randomly assigned to receive baricitinib 2 mg, baricitinib 4 mg or placebo, in addition to conventional DMARDs they were currently using. The study included 527 patients who had an inadequate response or intolerance to one or more TNF-inhibitor therapies. Patients could have had prior therapy with other bDMARDs.

The study results showed significantly higher ACR20 response rates and improvement in all individual ACR20 component scores at week 12 with use of baricitinib. Patients treated with baricitinib had significantly higher rates of ACR20 response versus patients treated with placebo at week 12 (49% of baricitinib-treated patients versus 27% of placebo-treated patients).

Baricitinib also demonstrated early symptom relief, with ACR20 responses seen as early as week 1. Patients reported significant improvements in physical function according to the Health Assessment Questionnaire Disability Index (HAQ-DI) (recording an average score of 1.71 before treatment and 1.31 at week 12) compared with placebo-treated patients (who recorded an average score of 1.78 before treatment and 1.59 at week 12).

Baricitinib is approved with a boxed warning for the risk...
FDA approves 2-mg dose of baricitinib to treat moderately to severely active RA in adults

(Lolumiant—Eli Lilly, Incyte)

Serious infections leading to hospitalization or death, including tuberculosis and bacterial, invasive fungal, viral, and other opportunistic infections, have occurred in patients receiving baricitinib.

Lymphoma and other malignancies have been observed in patients treated with baricitinib as well. In addition, thrombosis—including deep venous thrombosis, pulmonary embolism, and arterial thrombosis, some fatal—have occurred in some patients.

Other warnings and precautions include gastrointestinal perforations, laboratory abnormalities (including neutropenia, lymphopenia, anemia, liver enzyme elevations, and lipid elevations), and a warning against use of live vaccines with baricitinib.

The most common adverse events in clinical trials included upper respiratory tract infections, nausea, herpes simplex, and herpes zoster.

As part of the approval, the companies have agreed to conduct a randomized, controlled clinical trial to evaluate the long-term safety of baricitinib in patients with RA.

Source URL:
New Drug Approvals

Generic Name (Trade Name—Company)  |  Uses/Notes

June 5, 2018  |  FDA approved pegfilgrastim-jmdb as the first biosimilar to pegfilgrastim (Neulasta) to decrease the chance of infection as suggested by febrile neutropenia in patients with nonmyeloid (non–bone marrow) cancer who are receiving myelosuppressive chemotherapy that has a clinically significant incidence of febrile neutropenia.

Pegfilgrastim-jmdb  |  First pegfilgrastim biosimilar helps reduce the risk of infection during cancer treatment

(Fulphila—Mylan GmbH)  |  FDA’s approval of the new biosimilar was based on a review of evidence that included extensive structural and functional characterization, animal study data, human pharmacokinetic and pharmacodynamic data, clinical immunogenicity data, and other clinical safety and effectiveness data that demonstrates pegfilgrastim-jmdb is biosimilar to pegfilgrastim. It has been approved as a biosimilar, not as an interchangeable product.

Uses/Notes  |  The most common adverse effects are bone pain and pain in extremities. Patients with a history of serious allergic reactions to human granulocyte colony–stimulating factors such as pegfilgrastim or filgrastim products should not take the new biosimilar.

Uses/Notes  |  Serious adverse effects from treatment include rupture of the spleen, acute respiratory distress syndrome, serious allergic reactions including anaphylaxis, acute inflammation of the kidney, an abnormally high level of white blood cells, capillary leak syndrome, and the potential for tumor growth. Fatal sickle cell crises also have occurred.

Source URL:

Supplemental Approvals

Generic Name (Trade Name—Company) | Uses/Notes
--- | ---
June 8, 2018 | 
Methoxy polyethylene glycol-epoetin beta (Mircera—Vifor Pharma) | FDA approved methoxy polyethylene glycol-epoetin beta for the treatment of pediatric patients aged 5 to 17 years on hemodialysis who are converting from another erythropoietin-stimulating agent (ESA) after their hemoglobin level was stabilized with an ESA.

Approval was based on data from an open-label, multiple dose, multicenter, dose-finding trial in 64 pediatric patients (aged 5–17 y) with chronic kidney disease (CKD) on hemodialysis and had stable hemoglobin (Hb) levels while previously receiving another ESA (epoetin alfa/beta or darbepoetin alfa). Patients were administered methoxy polyethylene glycol-epoetin beta intravenously once every 4 weeks for 20 weeks. After the first administration, dosage adjustments were permitted to maintain target Hb levels.

Efficacy was based on maintaining Hb levels within target levels in the above clinical trial, and also from extrapolation from trials the agent in adult patients with CKD. The safety findings observed in pediatric patients were consistent with those previously reported in adults.

For conversion from another ESA, Mircera is dosed intravenously once every 4 weeks based on total weekly epoetin alfa or darbepoetin alfa dose at time of conversion. Full prescribing information is available at Mircera PI.

Source URL:
### Supplemental Approvals

<table>
<thead>
<tr>
<th>Generic Name (Trade Name—Company)</th>
<th>Uses/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>June 8, 2018</td>
<td></td>
</tr>
<tr>
<td><strong>Rituximab</strong></td>
<td>Genentech announced FDA approval of rituximab to treat adults with moderate to severe pemphigus vulgaris (PV), a rare, serious, potentially life-threatening condition characterized by progressive painful blistering of the skin and mucous membranes.</td>
</tr>
<tr>
<td><em>(Rituxan—Genentech)</em></td>
<td>Rituximab is the first biologic therapy approved by FDA for PV and the first major advancement in treatment of the disease in more than 60 years. The agent is now approved to treat four autoimmune diseases.</td>
</tr>
<tr>
<td>FDA approves first biologic therapy for pemphigus vulgaris</td>
<td>Approval was based on data from the Ritux 3 trial, a randomized, controlled trial conducted in France that used Roche-manufactured, European Union (EU)—approved rituximab product as the clinical trial material. The study compared the Ritux 3 regimen (EU-approved rituximab product plus short-term corticosteroids [CS]) to CS alone as a first-line treatment in patients with newly diagnosed moderate to severe pemphigus. The primary endpoint of the study was complete remission at month 24 without use of steroids for 2 or more months.</td>
</tr>
<tr>
<td></td>
<td>Results of the study showed that 90% of patients with PV treated with the Ritux 3 regimen met the endpoint, compared with 28% of patients with PV who were treated with CS alone. These results supported rituximab’s efficacy in treating patients with moderate to severe PV, while tapering off CS therapy.</td>
</tr>
<tr>
<td></td>
<td>Rituxan can cause serious adverse effects that can lead to death, including severe skin and mouth reactions, hepatitis B virus reactivation, and progressive multifocal leukoencephalopathy.</td>
</tr>
<tr>
<td></td>
<td>Common adverse effects include infusion reactions, infections (with fever and chills), body aches, tiredness, and nausea.</td>
</tr>
</tbody>
</table>

**Source URL:**
http://www.aphadruginfoline.com/supplemental-approvals/fda-approves-first-biologic-therapy-pemphigus-vulgaris
**New Drug Approvals**

**Generic Name (Trade Name—Company)**

June 8, 2018

**Venetoclax**

**FDA granted regular approval** to venetoclax for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.

Approval was based on MURANO, a randomized (1:1), multicenter, open-label trial of venetoclax with rituximab (VEN+R) versus bendamustine with rituximab (B+R) in 389 patients with CLL who had received at least one prior line of therapy. Patients in the VEN+R arm completed a 5-week ramp-up venetoclax schedule and then received venetoclax 400 mg once daily for 24 months measured from the rituximab start date.

Rituximab was initiated after venetoclax ramp-up and given for six cycles (375 mg/m\(^2\) intravenously on cycle 1, day 1 and 500 mg/m\(^2\) intravenously on day 1 of cycles 2–6, with a 28-day cycle length). The comparator arm received six cycles of B+R (bendamustine 70 mg/m\(^2\) on days 1 and 2 of each 28-day cycle and rituximab at the above described dose and schedule).

Efficacy was based on progression-free survival (PFS) as assessed by an independent review committee. After a median follow-up of 23 months, the median PFS was not reached in the VEN+R arm and was 18.1 months (95% CI 15.8–22.3) in the B+R arm (hazard ratio [HR] 0.19 [95% CI 0.13–0.28]; \(P < 0.0001\)). The overall response rate was 92% in the VEN+R arm compared with 72% for those treated with B+R.

In patients treated with VEN+R, the most common adverse reactions (incidence ≥20%) were neutropenia, diarrhea, upper respiratory tract infection, fatigue, cough, and nausea. Grade 3 or 4 neutropenia developed in 64% of these patients, and grade 4 neutropenia developed in 31%.

Serious adverse reactions occurred in 46% of patients. Serious infections developed in 21% of patients, most commonly pneumonia (9%).

Due to rapid reduction in tumor volume, tumor lysis syndrome (TLS) is an important identified risk with...
FDA approves new drug for CLL or SLL, with or without 17 p deletion, after one prior therapy

venetoclax treatment. See the prescribing information for TLS risk stratification, prophylaxis, and monitoring.

All approved venetoclax regimens begin with a 5-week ramp-up. Full prescribing information is available at Venclexta PI.

Source URL:
Supplemental Approvals

Generic Name (Trade Name—Company)  Uses/Notes

June 14, 2018

Pembrolizumab

FDA granted accelerated approval of pembrolizumab to treat patients with cancer whose unresectable or metastatic solid tumors have a specific genetic feature (biomarker), referred to as microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). This is the first time the agency has approved a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.

This indication covers patients with solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options and patients with colorectal cancer that has progressed following treatment with certain chemotherapy drugs.

MSI-H and dMMR tumors contain abnormalities that affect the proper repair of DNA inside the cell. Tumors with these biomarkers are most commonly found in colorectal, endometrial, and gastrointestinal cancers but also less commonly appear in cancers arising in the breast, prostate, bladder, thyroid gland, and other places. Approximately 5% of patients with metastatic colorectal cancer have MSI-H or dMMR tumors.

Pembrolizumab works by targeting the PD-1/PD-L1 cellular pathway. By blocking this pathway, the drug may help the body’s immune system fight the cancer cells. FDA previously approved the agent to treat certain patients with metastatic melanoma, metastatic non–small cell lung cancer, recurrent or metastatic head and neck cancer, refractory classical Hodgkin lymphoma, and urothelial carcinoma.

Safety and efficacy of pembrolizumab for this indication were studied in patients with MSI-H or dMMR solid tumors who were enrolled in one of five uncontrolled, single-arm clinical trials. In some trials, patients were required to have MSI-H or dMMR cancers, while in other trials, a subgroup of patients were identified as having MSI-H or dMMR cancers by testing tumor samples after treatment began.

A total of 15 cancer types were identified among 149 patients enrolled across these five clinical trials. The
most common cancers were colorectal, endometrial, and other gastrointestinal cancers. Approval for this indication was based on the percentage of patients who experienced complete or partial shrinkage of their tumors (overall response rate) and for how long (durability of response). Of the 149 patients who received pembrolizumab in the trials, 39.6% had a complete or partial response. For 78% of those patients, the response lasted for 6 months or more.

Common adverse effects include fatigue, pruritus, diarrhea, decreased appetite, rash, fever, cough, difficulty breathing, musculoskeletal pain, constipation, and nausea.

Pembrolizumab can cause serious conditions, known as immune-mediated adverse effects, including inflammation of healthy organs such as the lungs (pneumonitis), colon (colitis), liver (hepatitis), endocrine glands (endocrinopathies), and kidneys (nephritis). Complications or death related to allogeneic hematopoietic stem cell transplantation after using pembrolizumab has occurred.

Patients who experience severe or life-threatening infusion-related reactions should stop taking pembrolizumab. Women who are pregnant or breastfeeding should not take pembrolizumab because it may cause harm to a developing fetus or newborn baby.

Safety and effectiveness of the agent in pediatric patients with MSI-H central nervous system cancers have not been established.

Source URL:
FDA approved bevacizumab for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab, for Stage III or IV disease after initial surgical resection.

Approval was based on a multicenter, randomized, double-blind, placebo-controlled, three-arm study evaluating the addition of bevacizumab to carboplatin and paclitaxel for patients with Stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection.

A total of 1,873 patients were randomized to carboplatin plus paclitaxel without bevacizumab, carboplatin plus paclitaxel with bevacizumab for up to six cycles, or carboplatin plus paclitaxel with bevacizumab for six cycles followed by single-agent bevacizumab for up to 16 additional doses. Bevacizumab was administered at 15 mg/kg intravenously every 3 weeks. On this trial, 1,215 patients received at least one bevacizumab dose.

The primary efficacy outcome was investigator-assessed progression-free survival (PFS); overall survival (OS) was a secondary outcome. The estimated median PFS was 18.2 months for patients receiving bevacizumab with chemotherapy followed by single-agent bevacizumab (hazard ratio [HR] 0.62 [95% CI 0.52–0.75]; P < 0.0001). For those receiving bevacizumab with chemotherapy without single-agent bevacizumab, the estimated median PFS was 12.8 months (HR 0.83 [95% CI 0.70–0.98]; not significant).

For patients receiving chemotherapy without bevacizumab, the estimated median PFS was 12.0 months. Estimated median OS was 43.8 months in the bevacizumab with chemotherapy followed by bevacizumab, compared with 40.6 months in the chemotherapy alone arm (HR 0.89 [95% CI 0.76–1.05]).

Adverse reactions occurring at higher incidence (at least 5%) of patients receiving bevacizumab were diarrhea, nausea, stomatitis, fatigue, arthralgia, muscular weakness, pain in extremity, dysarthria, headache,
dyspnea, epistaxis, nasal mucosal disorder, and hypertension.

Grade 3-4 adverse reactions occurring at a higher incidence (≥2%) in either of the bevacizumab arms versus the control arm were fatigue, hypertension, decreased platelet count, and decreased white blood cell count.

The recommended bevacizumab dose for Stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection is 15 mg/kg every 3 weeks with carboplatin and paclitaxel for up to six cycles, followed by 15 mg/kg every 3 weeks as a single agent, for a total of up to 22 cycles.

Source URL:
Supplemental Approvals

June 15, 2018

Buprenorphine and naloxone

FDA approved the first generic versions of Suboxone (buprenorphine and naloxone) sublingual film for the treatment of opioid dependence.

Medication-assisted treatment (MAT) is a comprehensive approach that combines FDA-approved medications (currently methadone, buprenorphine, or naltrexone) with counseling and other behavioral therapies to treat patients with opioid use disorder (OUD). Regular adherence to MAT with buprenorphine reduces opioid withdrawal symptoms and the desire to use opioids, without causing the cycle of highs and lows associated with opioid misuse or abuse.

At proper doses, buprenorphine also decreases the pleasurable effects of other opioids, making continued opioid abuse less attractive. According to the Substance Abuse and Mental Health Services Administration, patients receiving MAT for treatment of their OUD cut their risk of death from all causes in half.

One of the ways FDA is encouraging access and wider use of MAT is through the approval of generic versions of these products. Generic drugs approved by FDA have, among other things, the same quality as brand-name drugs. Generic drug manufacturing and packaging sites must meet the same quality standards as those of brand-name drugs.

Adverse events commonly observed with the buprenorphine and naloxone sublingual film are oral hypoesthesia (numbness), glossodynia (burning mouth), oral mucosal erythema (inflammation of oral mucous membrane), headache, nausea, vomiting, hyperhidrosis (excessive sweating), constipation, signs and symptoms of withdrawal, insomnia, pain, and peripheral edema (accumulation of fluid causing swelling in lower limbs). These products may only be prescribed by Drug Addiction Treatment Act (DATA)-certified prescribers.

Mylan Technologies and Dr. Reddy's Laboratories received approval to market buprenorphine and naloxone sublingual film in multiple strengths. Buprenorphine and naloxone sublingual film should be
(Suboxone—Mylan Technologies, Dr. Reddy’s Laboratories)

FDA approves first generic versions of sublingual film to treat opioid dependence

used as part of a complete treatment plan that includes counseling and psychosocial support.

Source URL:
New Drug Approvals

<table>
<thead>
<tr>
<th>Generic Name (Trade Name—Company)</th>
<th>Uses/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>June 15, 2018</td>
<td></td>
</tr>
<tr>
<td><strong>Moxidectin</strong></td>
<td></td>
</tr>
<tr>
<td><em>(No trade name—Medicines Development for Global Health)</em></td>
<td></td>
</tr>
<tr>
<td>Medication treats river blindness in patients aged 12 years and older</td>
<td></td>
</tr>
</tbody>
</table>

FDA has approved moxidectin 8-mg tablets to treat river blindness (*onchocerciasis*) in patients aged 12 years and older. FDA has also awarded a priority review voucher (PRV) to the manufacturer, Medicines Development for Global Health (MDGH).

River blindness is caused by a parasitic worm, *Onchocerca volvulus*. The disease manifests as severe itching, disfiguring skin conditions, and visual impairment, including permanent blindness, caused by the worm’s larvae (microfilariae).

Approval of moxidectin was based on data from two randomized, double-blind, active controlled clinical studies. Each study met its respective primary endpoints, showing a statistically significant superiority of moxidectin over the current standard of care, ivermectin, in suppressing the presence of the microfilariae in skin. Full results from the Phase III study were published in the *Lancet* in January 2018.

Moxidectin is supplied as 2-mg tablets for administration as an 8-mg dose per oral to patients at least 12 years of age with *O. volvulus* infection.

Source URL:

http://www.aphadruginfoline.com/new-drug-approvals/medication-treats-river-blindness-patients-aged-12-years-and-older
### Alerts and Recalls

<table>
<thead>
<tr>
<th>Generic Name (Trade Name—Company)</th>
<th>Uses/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>June 15, 2018</td>
<td></td>
</tr>
</tbody>
</table>

**Triamcinolone and moxifloxacin**

(No trade names—Guardian Pharmacy Services)

**FDA warns of adverse events from compounded product for intravitreal injection**

FDA is alerting health professionals of adverse events associated with a drug containing triamcinolone (a steroid) and moxifloxacin (anti-infective) compounded by Guardian Pharmacy Services in Dallas. FDA received adverse event reports on April 5 and June 1, 2017, and conducted follow-up concerning at least 43 patients who were administered intravitreal (eye) injections of the drug at the end of a cataract surgery procedure at the PRG Dallas Ambulatory Surgery Center.

The purpose of the injection was to provide postoperative prophylaxis for ocular inflammation and endophthalmitis with the expectation that the patient would not need to use postoperative eye drops.

Over the course of several months, patients developed various symptoms, including vision impairment (blurred or decreased vision), poor night vision, loss of color perception, photophobia (light sensitivity), glare, halos, flashing lights, ocular discomfort, pain, loss of balance, headaches, and/or nausea. A number of the symptoms were not exhibited until at least 1 month postoperatively.

During follow-up examinations, physicians observed that the patients had diminished visual function involving both visual acuity and visual fields. Optical coherence tomography testing initially showed macular edema, which was followed in some cases by retinal degeneration. While the symptoms reportedly improved in some patients over the 5-month postoperative period, a number of patients remain with a significant reduction in best-corrected visual acuity and visual fields.

**Source URL:**

## Supplemental Approvals

<table>
<thead>
<tr>
<th>Generic Name (Trade Name—Company)</th>
<th>Uses/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pembrolizumab (Keytruda—Merck)</td>
<td></td>
</tr>
</tbody>
</table>

### New indication for treatment of refractory or relapsed PMBCL

Merck announced FDA approval of pembrolizumab to treat adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL) or relapsed PMBCL after two or more prior lines of therapy. With this indication, pembrolizumab becomes the first anti-PD-1 therapy to be approved for treatment of PMBCL, a type of non-Hodgkin lymphoma. It is the second indication for the agent for treatment of a hematologic malignancy.

This indication was approved under the FDA’s accelerated approval regulations based on tumor response rate and durability of response.

The agent is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy.

Immune-mediated adverse reactions include pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, severe skin reactions and solid organ transplant rejection. Because of the severity of the adverse reaction, pembrolizumab should be withheld or discontinued and corticosteroids administered if appropriate. Immune-mediated complications, including fatal events, occurred in patients with classical Hodgkin lymphoma who underwent allogeneic hematopoietic stem cell transplantation after treatment with pembrolizumab.

### Source URL:

http://www.aphadruginfoline.com/supplemental-approvals/new-indication-treatment-refractory-or-relapsed-pmbcl